



COLORADO

Department of Health Care
Policy & Financing

AGENDA
Pharmaceuticals & Therapeutics Committee
Department of Health Care Policy & Financing

Zoom Webinar Registration:

https://magellanhealth.zoom.us/webinar/register/WN_tyecFfjvR6qL5seTgPKsPg

Tuesday, January 10, 2023, 1:00-5:00 P.M.

1. Committee Member Introductions

Introduction of New Members

Vote for Committee Positions - Chairperson, Vice Chairperson

2. Unfinished Business and General Orders

Approval of minutes from October 4, 2022, P&T meeting

Updates from October 4, 2022, P&T Meeting

Hepatitis C Virus Treatments

Direct Acting Antivirals, Ribavirin

Human Immunodeficiency Virus (HIV) Treatments

Intranasal Rhinitis Agents

Targeted Immune Modulators

Asthma, Other Agents

Newer Hereditary Angioedema (HAE) Products

Mass review drug classes:

Antibiotics, Inhaled

Antiherpetic Agents

Oral, Topical

Fluoroquinolones, Oral

Immune Globulins

Antihistamines

Newer Generation, Antihistamine/Decongestant Combinations

Leukotriene Modifiers

Methotrexate Products

Epinephrine Products

Respiratory Agents

Inhaled Anticholinergics & Combinations

Inhaled Beta2 Agonists (Short & Long-Acting)

Inhaled Corticosteroids & Combinations

Phosphodiesterase Inhibitors (PDEIs)

Improving health care equity, access, and outcomes for the people we serve while
saving Coloradans money on health care and driving value for Colorado.

www.colorado.gov/hcpf



3. New Business

Updates from the Prior Authorization Call Center

4. Drug Classes Up for Review

- Review of Non-Opioid Analgesia Agents - Oral & Topical
- Review of Opioids - Short-Acting, Fentanyl Preparations, Long-Acting
- Review of Anticonvulsants, Oral
- Review of Newer Generation Antidepressants
- Review of Atypical Antipsychotics - Oral/Topical
- Review of Neurocognitive Disorder Agents
- Review of Sedative Hypnotics
- Review of Skeletal Muscle Relaxants
- Review of Stimulants and Related Agents
- Review of Triptans, Ditans, and Other Migraine Treatments - Oral & Non-Oral
- Review of Multiple Sclerosis Therapies - Disease Modifying & Symptom Management
- Review of Ophthalmics, Immunomodulators

Mass review drug classes:

- Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) - Oral & Non-Oral
- Monoamine Oxidase Inhibitors (MAOIs)
- Tricyclic Antidepressants (TCAs)
- Anti-Parkinson's Agents
- Benzodiazepines (Non-Sedative Hypnotic)
- Anxiolytics, Non-Benzodiazepine
- Calcitonin Gene-Related Peptide Inhibitors (CGRPIs)
- Lithium Agents
- Ophthalmics, Allergy
- Ophthalmics, Anti-Inflammatories
- Ophthalmics, Glaucoma

Each Review will contain:

- Oral presentation by manufacturers, providers, and public
- Overview for each Drug Class, including market share overview
- Committee Discussion and Recommendations for each Class

Mass Review drug classes will only include:

- Overview for each Drug Class, including market share overview

Presentations:



- Interested parties who want to present at the meeting shall give advanced notice and provide a one-page summary of the clinical testimony that will be presented for P&T Committee dissemination.
- Advance notice requests to present and/or written public comments can be submitted to Jessica Czechowski, Pharmacist Account Executive, jlczechowski@magellanhealth.com and carbon copy: Brittany Schock, PDL Pharmacist, brittany.schock@state.co.us. Once approved, public comments will be distributed to P&T Committee Members.
- Requests and public comment summaries are due by **January 3rd, 2023, by 5pm MST**.

5. Adjourn

Upcoming Meeting Date: April 4, 2023.

Reasonable accommodations will be provided upon request. Auxiliary aids and services for individuals with disabilities and language services for individuals whose first language is not English may be provided upon request. Please notify the [504/ADA Coordinator](#) or hcpf504ada@state.co.us at least one week prior to the meeting to make arrangements.

